PONVORY™ (ponesimod) HCP

PONVORY™ WAS PROVEN SUPERIOR AT REDUCING RELAPSES AND LESIONS VS AUBAGIO® IN A STUDY LASTING ~2 YEARS1

PONVORY™: a new oral, once-daily, selective S1P1 therapy for relapsing MS in adults1-3*

ARR = annualized relapse rate; GdE = gadolinium-enhancing; PD = pharmacodynamic; PK = pharmacokinetic; S1P1 = sphingosine-1-phosphate 1.

*The exact mechanism by which PONVORY™ exerts therapeutic effects in MS is unknown but may involve reduction of lymphocyte migration into the central nervous system.1

As studied in OPTIMUM, a 108-week, randomized, double-blind, phase 3 study.1

First-dose, 4-hour monitoring is recommended for patients with sinus bradycardia (heart rate <55 beats per minute), first- or second-degree atrioventricular block (Mobitz type I), or a history of myocardial infarction or heart failure occurring >6 months prior to treatment initiation and in stable condition.1

References: 1. PONVORY™. Prescribing information. Janssen Pharmaceuticals, Inc; 2021. 2. Bolli MH, Abele S, Binkert C, et al. 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. J Med Chem. 2010;53(10):4198-4211. doi:10.1021/jm100181s 3. D'Ambrosio D, Freedman MS, Prinz J. Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases. Ther Adv Chronic Dis. 2016;7(1):18-33. doi:10.1177/2040622315617354 4. Kappos L, Burcklen M, Freedman MS, et al. Efficacy and safety of ponesimod compared to teriflunomide in patients with relapsing multiple sclerosis: results of the randomized, active-controlled, double-blind, parallel-group phase 3 OPTIMUM study. Poster presented at: European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2019; September 11-13, 2019. 5. Data on file. Interim Clinical Study Report. Janssen Pharmaceuticals, Inc; 2020.